SciSparc Ltd. (NASDAQ:SPRC – Get Free Report)’s share price traded up 2% on Monday . The stock traded as high as $4.64 and last traded at $4.60. Approximately 4,701 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 25,245 shares. The stock had previously closed at $4.51.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of SciSparc in a research report on Friday, August 21st. Wall Street Zen raised SciSparc to a “hold” rating in a research note on Saturday, July 18th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.
Read Our Latest Stock Report on SPRC
SciSparc Price Performance
About SciSparc
SciSparc Ltd. (NASDAQ: SPRC) is an Israel-based specialty pharmaceutical company focused on developing therapies that combine cannabinoids with other pharmaceutical compounds. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including neurological and central nervous system disorders.
SciSparc has developed a pipeline that has included SCI-110, an investigational cannabinoid-based treatment being studied for conditions such as Tourette syndrome and Alzheimer’s disease-related agitation, and SCI-210, a combination therapy under development for autism spectrum disorder.
Further Reading
- Five stocks we like better than SciSparc
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for SciSparc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciSparc and related companies with MarketBeat.com's FREE daily email newsletter.
